Extraordinary response of metastatic pancreatic cancer to apatinib after failed chemotherapy: A case report and literature review

Table 1 Clinical trials using targeted agents for advanced or metastatic pancreatic cancer

Target medicine	Mechanism	Phase	Stage	n	Arm	PFS, mo	OS, mo	ORR
Cetuximab[27]	EGFR	III	Locally advanced/metastatic	746	A: GEM + cetuximab	3.4 vs 3.0	6.3 vs 5.9	49% vs 44%
					B: GEM	P = 0.18	P = 0.23	P = 0.59
Nimotuzumab[28]	EGFR	III	Locally advanced/metastatic	18	GEM + nimotuzumab	3.71	9.29	55.50%
Lapatinib[29]	EGFR + Her-2	II	Metastatic	17	Lapatinib + capecitabine	2.6	5.2	-
Cixutumumab[30]	IGF-1R	Ib/II	Metastatic	116	A: Erlotinib + cixutumumab + GEM	3.6 vs 3.6	7.0 vs 6.7	12.28% vs 15.25%
					B: Erlotinib + GEM	P = 0.97	P = 0.64
Cetuximab +Everolimus[31]	EGFR + mTOR	II	Locally advanced/metastatic	31	Everolimus+ cetuximab + capecitabine	-	5.0	22.60%
Cetuximab + trastuzumab[32]	EGFR + Her-2	I-II	Metastatic	33	Cetuximab + trastuzumab	1.8	4.6	-
Erlotinib + Selumetinib[33]	EGFR + MEK1/2	II	Locally advanced/metastatic	46	Erlotinib + selumetinib	1.9	7.3	-

EGFR: Epidermal growth factor receptor; GEM: Gemcitabine; ORR: Objective response rate.